[Treatment of the diffuse and focal proliferative forms of lupus nephropathy with intravenous @entity786 . Intravenous XXXX in systemic lupus erythematosus].

@entity1 @entity644 @entity137 @entity786 @entity1988 @entity811 @entity2335
The objective is to evaluate the therapeutic effect and @entity137 of IV @entity786 on the evolution of diffuse and focal proliferative forms of @entity1988 . It's a prospective, descriptive and non-controlled study. We treated 12 @entity1 (M/F = 1:11, aged 30.07 +/- 14.15) diagnosed by renal biopsy with diffuse proliferative (n = 10) and focal (n = 2) @entity1988 . All @entity1 received IV @entity786 . A dose of 1 g/sg.m of body surface area was administered monthly for the first three months and each three months until two years. The follow-up was 34 +/- 24.83 months (range 6-67). Seven @entity1 completed two years of treatment with @entity786 with a further follow-up of 18.71 +/- 12.36 months (range 6-67). Renal function either improved or remained unchanged. @entity644 , @entity811 and immunologic markers decreased or normalized at three years. The @entity1 who finished the period of two years with CFIV remained stable. There were neither infections nor @entity2335 . We conclude that with the scheme of CFIV used by us good therapeutics effects will be obtained with minimum secondary @entity137 in a follow-up of three to five years.
